Ranibizumab for choroidal neovascularization in fundus flavimaculatus

Retin Cases Brief Rep. 2008 Summer;2(3):250-2. doi: 10.1097/ICB.0b013e31816b31d1.

Abstract

Purpose: To report the features of a case with late-onset fundus flavimaculatus (FFM) complicated by choroidal neovascularization (CNV) and treated with ranibizumab.

Methods: Retrospective interventional case report.

Patient: A 51-year-old woman presented with right eye decreased vision. Fundus flavimaculatus with CNV was diagnosed by electroretinography and fluorescein angiography.

Results: Two intravitreal injections of ranibizumab were needed for the treatment. At the end of follow-up (9 months) no leakage was observed and visual acuity improved.

Conclusion: Choroidal neovascularization is a rare complication of FFM. Ranibizumab, an anti-VEFG drug, stopped neovascularization and improved final visual acuity in this case, so it must be considered in the treatment of CNV in late onset FFM.